scPharmaceuticals (SCPH) AI Stock Analysis

• Market Cap: $213.28M
• Dividend Yield: N/A
• Average Volume (3M): 289.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 138.10%
• EPS Growth: -28.59%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 52,791,977
• 10 Day Avg. Volume: 284,999
• 30 Day Avg. Volume: 289,573
• PEG Ratio: -0.29
• Price to Book (P/B): -0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.88
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 5.86
• Enterprise Value/Ebitda: -0.60
• 1Y Price Target: $15.60
• Price Target Upside: 286.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 49 Neutral
• Price Target: $4.00 ▼(-0.99%Downside)

scPharmaceuticals' stock score is primarily influenced by its challenging financial position, with high debt levels and negative cash flows. While technical indicators suggest strong momentum, the potential near-term pullback due to overbought conditions and the negative valuation metrics indicate caution. The earnings call provided positive insights, but its impact is not included in the weighted score.

Positive Factors

Market Expansion

The expansion to CKD is a significant market opportunity and expands Furoscix’s prescriber base to nephrologists.

Product Launch Success

Furoscix launched promotional efforts for Chronic Kidney Disease and is being positively received, with progress faster than the initial heart failure launch.

Revenue Growth

ScPharmaceuticals reported 1Q25 results with revenue of $11.8M, up 92.6% year-over-year, beating consensus and estimates.

Negative Factors

Sales Forecast Adjustment

The long-term peak sales forecast for Furoscix in heart failure and chronic kidney disease has been lowered to reflect a more measured uptake trajectory.

Sales Trajectory

The long-term peak sales forecast for Furoscix in heart failure and chronic kidney disease has been lowered to reflect a more measured uptake trajectory.

scPharmaceuticals Business Overview & Revenue Model

Company Description

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

How the Company Makes Money

scPharmaceuticals makes money through the development and commercialization of its proprietary pharmaceutical products. The company's primary revenue stream is derived from the sale of FUROSCIX®, a subcutaneous formulation of furosemide intended for use outside of a hospital setting. Revenue is generated when healthcare providers, patients, or healthcare systems purchase the product. scPharmaceuticals may also engage in partnerships or collaborations with other pharmaceutical companies to expand the reach and effectiveness of its products, potentially leading to milestone payments or royalties. Additionally, the company invests in ongoing research and development to expand its product pipeline, which could result in future revenue opportunities.

scPharmaceuticals Financial Statement Overview

Summary

scPharmaceuticals shows promising revenue growth but faces significant challenges in profitability, leverage, and cash flow. The high debt levels and negative equity position indicate financial instability, while negative cash flows suggest ongoing operational difficulties. Improving operational efficiency and financial health is essential for future stability and growth.

Income Statement

The company demonstrated a significant increase in revenue from 2023 to 2024, showing positive growth potential. However, profitability remains a concern, with consistent net losses and negative EBIT and EBITDA margins, indicating challenges in achieving operational efficiency and profitability.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Negative stockholders' equity is a concern, suggesting liabilities exceed assets, which may pose financial stability risks. The equity ratio is negative, highlighting the company's reliance on debt financing.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow is also negative, indicating cash outflows exceed cash inflows, which may impact the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.98M	36.33M	13.59M	0.00	0.00	0.00
Gross Profit	28.93M	24.97M	9.78M	-468.00K	-438.00K	-399.00K
EBITDA	-83.21M	-77.43M	-46.06M	-33.07M	-25.02M	-29.22M
Net Income	-90.78M	-85.15M	-54.81M	-37.52M	-30.49M	-34.39M
Balance Sheet
Total Assets	90.96M	107.52M	94.48M	124.19M	79.04M	109.05M
Cash, Cash Equivalents and Short-Term Investments	57.54M	75.66M	76.01M	118.37M	75.46M	105.28M
Total Debt	52.36M	52.69M	40.27M	37.37M	17.64M	20.21M
Total Liabilities	96.09M	94.20M	57.26M	51.76M	22.57M	26.88M
Stockholders Equity	-5.13M	13.32M	37.22M	-226.54M	-189.70M	-161.66M
Cash Flow
Free Cash Flow	-70.00M	-70.56M	-59.28M	-34.60M	-27.16M	-27.69M
Operating Cash Flow	-69.98M	-70.54M	-59.24M	-34.58M	-27.15M	-27.69M
Investing Cash Flow	-20.00K	29.30M	19.96M	-45.86M	32.13M	-33.46M
Financing Cash Flow	69.09M	70.08M	14.85M	77.23M	-2.53M	60.35M

scPharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPH, the sentiment is Positive. The current price of 4.04 is above the 20-day moving average (MA) of 4.01, above the 50-day MA of 3.34, and above the 200-day MA of 3.51, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 58.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCPH.

scPharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	59 Neutral	$274.42M	―	-91.44%	―	-2.04%	83.49%
NKTR	54 Neutral	$316.75M	―	-189.46%	―	-3.24%	31.00%
RGLS	52 Neutral	$564.95M	―	-53.82%	―	―	44.85%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
LRMR	49 Neutral	$199.13M	―	-50.77%	―	―	-54.29%
SCPH	49 Neutral	$213.28M	―	-934.02%	―	138.10%	-28.59%
KOD	35 Underperform	$202.08M	―	-108.92%	―	―	32.58%

scPharmaceuticals Corporate Events

scPharmaceuticals Holds Annual Stockholders Meeting June 2025

On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.

The most recent analyst rating on (SCPH) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.